Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

BACKGROUND: Since atezolizumab plus bevacizumab (ATE+BEV) regimen for patients with unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data are lacking. We evaluated efficacy, safety, and predictive biomarkers for survival in patients receiving ATE+BEV. METHODS: Betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Chon, Young Eun, Cheon, Jaekyung, Kim, Hyeyeong, Kang, Beodeul, Ha, Yeonjung, Kim, Do young, Hwang, Seong Gyu, Chon, Hong Jae, Kim, Beom Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939088/
https://www.ncbi.nlm.nih.gov/pubmed/35997637
http://dx.doi.org/10.1002/cam4.5161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939088/
https://www.ncbi.nlm.nih.gov/pubmed/35997637
http://dx.doi.org/10.1002/cam4.5161

Ejemplares similares